Welcome to our dedicated page for Bone Biologics SEC filings (Ticker: bblgw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
a publicly-held biotechnology company that is a spin off of the musculoskeletal transplant foundation (mtf) using technology discovered and licensed from ucla. bone biologics market and focus is in the regenerative medicine orthobiologics space. bone biologics was founded in 2004 by university of california professors in collaboration with an osaka university professor and a usc surgeon and acquired in 2006 by mtf as the major shareholder, who has been the primary funder since the acquisition. the company’s proprietary, patented platform technology ucb-1™, exclusively licensed from ucla, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and rhesus monkey) studies that have demonstrated that the ucb-1™ technology facilitates superior normal bone growth. the company believes that as a platform technology, ucb-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.Bone Biologics Corporation is updating its at-the-market equity offering program to permit sales of up to $1,064,000 of common stock through H.C. Wainwright & Co. as sales agent under an existing sales agreement. These potential sales are covered by a prospectus supplement dated March 13, 2026, tied to the company’s effective Form S-3 shelf registration statement. The company previously sold approximately $1.7 million of common stock under the same sales agreement using an earlier shelf registration, which is no longer effective. A legal opinion regarding the validity of the shares covered by the new prospectus supplement is filed as an exhibit.
Bone Biologics Corporation is offering up to $1,064,000 of common stock through an at‑the‑market sales agreement with H.C. Wainwright & Co., enabling periodic sales into the Nasdaq market. As of March 13, 2026, the company had previously issued 195,722 shares for gross proceeds of $1,678,036 under the same program.
The prospectus supplement states 1,795,260 shares outstanding prior to this offering (as of March 13, 2026) and models up to 2,626,510 shares outstanding after this offering assuming sale of 831,250 shares at $1.28 per share. Net proceeds are designated to fund clinical trials, maintain and extend the patent portfolio, and for working capital. The filing discloses an auditor going concern explanatory paragraph and highlights that additional capital will be required to continue operations.
Bone Biologics Corporation files its annual report outlining a clinical-stage spine fusion business built around its NELL-1/DBM bone regeneration platform licensed from UCLA. The company is running a first-in-man pilot lumbar fusion study in Australia and plans a future U.S. pivotal trial.
Bone Biologics reports a net loss of approximately $3.1 million for the year ended December 31, 2025 and an accumulated deficit of about $88.1 million, with its auditor expressing substantial doubt about its ability to continue as a going concern. Available cash is expected to fund operations into the fourth quarter of 2026, and the company warns it must raise additional capital, navigate extensive FDA and international regulation, and meet significant royalty and milestone obligations under its exclusive UCLA license while competing against much larger orthopedic players.
Bone Biologics Corp reported an insider equity award for its Chief Financial Officer, Deina Walsh, on a Form 4. On January 8, 2026, she received an employee stock option covering 8,335 shares of common stock with an exercise price of $1.55 per share. According to the filing, this option was granted under the company’s 2015 Equity Incentive Plan and vests and becomes exercisable immediately, with an expiration date of January 8, 2036.
The filing also shows she holds another employee stock option for 4,510 shares at an exercise price of $5.82, which is fully vested and expires on January 15, 2027, as well as 313 shares of common stock held directly after the reported transactions.
Bone Biologics Corp reported an insider equity award for its Chief Executive Officer, Jeff Frelick. On January 8, 2026, he received an employee stock option grant covering 16,668 shares of common stock with an exercise price of $1.55 per share. The filing states that this option was granted under the company’s 2015 Equity Incentive Plan, is exempt under Rule 16b-3, and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.
After this grant, Frelick directly holds 16,668 of these new options, along with previously held, fully vested options on 9,019 shares at an exercise price of $5.82 and options on 8 shares at an exercise price of $73,800. He also directly owns 360 shares of Bone Biologics common stock.
Bone Biologics Corporation filed a current report to share that its Chief Executive Officer issued a letter to stockholders. On September 4, 2025, the company released a press release discussing this CEO letter, and that press release is attached as Exhibit 99.1 to the report and incorporated by reference. The company’s common stock and related warrants trade on the Nasdaq Capital Market under the symbols BBLG and BBLGW, respectively.
Bone Biologics Corporation is updating its shelf registration statement on Form S-3 to carry forward $17,592,964 of previously registered but unsold securities under Rule 415(a)(6). The company states that, upon effectiveness of this new registration, the offering of these unsold securities under its prior registration statement (File No. 333-265872) will be deemed terminated and the previously paid $1,630.87 filing fee will be applied to this filing. This Amendment No. 1 is being filed solely to add the consent of its independent registered public accounting firm as Exhibit 23.1, with all other parts of the registration statement unchanged.